<DOC>
	<DOCNO>NCT01902251</DOCNO>
	<brief_summary>A multiple dose relative bioavailability study patient prostate cancer compare capsule tablet formulation enzalutamide .</brief_summary>
	<brief_title>Relative Bioavailability Study Enzalutamide Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm prostate cancer ( stage ) androgen deprivation therapy indicate ( except indicate neoadjuvant/adjuvant setting ) . Subjects may ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue orchiectomy ( i.e. , medical surgical castration ) study entry . Progressive disease Prostatespecific antigen ( PSA ) imaging . Disease progression study entry define one follow 3 criterion : PSA progression define minimum 2 rise PSA level interval ≥1 week determination . The PSA value preinvestigational period ≥2 μg/L ( 2 ng/mL ) ; Soft tissue disease progression define Response Evaluation Criteria Solid Tumors , version 1.1 ( RECIST 1.1 ) soft tissue disease Bone disease progression define two new lesion bone scan Treatment chemotherapy within 4 week prior enrollment ( Day 1 visit ) plan initiate treatment chemotherapy study . History seizure condition may predispose seizure . Also , history loss consciousness , transient ischemic attack within 12 month prior enrollment ( Day 1 visit ) . Patients previously receive treatment Enzalutamide . Concomitant use drug potent inducer and/or inhibitor CYP3A4 CYP2C8 . Confirmed CYP2C8 poor metabolizer status base genotyping analysis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Food effect</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Xtandi</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>MDV3100</keyword>
</DOC>